Access and Evidence
Prescription drug pricing: The times they are a changin’
The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value
More Access and Evidence Articles
Access and Evidence
Putting a price on life: Is the answer outside pharma?
Gene replacement and cell-based therapies are here to cure, but are we ready for them? The current difficulty pricing groundbreaking healthcare advancements suggests maybe not.
Access and Evidence
Putting The I in Pills
Individualised medicine has so far failed to live up to the hype but innovations in the field are on the cusp of disrupting the way pharma and healthcare develop and provide treatments.
Access and Evidence
Embracing Early Access
Compassionate use programs offer hope to patients who have ran out of options. But the benefits must be weighed against the risks.
Access and Evidence
RWE: The Missing Link
Linking real-world datasets is essential to deliver true insights
Access and Evidence
Gold Standard: Standardizing RWD
If real-world data is to deliver on its promise, it needs to be standardized
Access and Evidence
Blockchain: Solution Or Snake Oil?
The potential of blockchain to better manage RWE and access makes it an exciting prospect. However, pharma first needs to get its head around the practical application.
Access and Evidence
VBCs: Are They Working?
Are value-based contracts actually improving patient access to new medicines?
Access and Evidence
Calling the Shots?
How influential are the value assessments from bodies like ICER?